Literature DB >> 28866386

Effects of orally self-administered bath salt constituent 3,4-methylenedioxypyrovalerone (MDPV) in mice.

Brenda M Gannon1, Lauren N Russell1, Meet S Modi2, Kenner C Rice3, William E Fantegrossi4.   

Abstract

Synthetic cathinones in bath salts products are psychostimulant drugs of abuse, and 3,4-methylenedioxypyrovalerone (MDPV) is a common constituent of these products. Oral MDPV has been show to stimulate locomotor activity but reinforcing, locomotor and appetitive stimulus effects of oral MDPV are unknown. Choice procedures evaluated preference for 0.03, 0.10, 0.30, and 1.00mg/mL MDPV solutions versus 0.10mg/mL quinine solution or water. To verify that oral MDPV produced pharmacological effects, locomotor activity was monitored during and after consumption of water, quinine, or MDPV solutions. Conditioned place preference (CPP) tested the apparent appetitive effects of a preferred concentration of oral MDPV with locomotor stimulant effects (0.30mg/mL), using water as a control, and compared with results from intraperitoneally-administered MDPV. Consumption of MDPV solutions (0.03-1.00mg/mL) was low when the alternative fluid was water, but a history of MDPV consumption increased MDPV choice. When paired with a quinine control solution, MDPV solutions (0.03-0.30mg/mL) were almost exclusively preferred, and treatment with the catecholamine synthesis inhibitor αMPT decreased MDPV choice. Consumption of MDPV concentrations (0.1-1.0mg/mL) stimulated locomotor activity. Chronic (10day) access to 0.30mg/mL MDPV resulted in escalated consumption, but locomotor effects did not systematically change across the access period. Finally, consumption of 0.30mg/mL MDPV elicited CPP with a magnitude similar to the preference observed following intraperitoneal administration of MDPV. Consistent with human abuse patterns, oral MDPV has reinforcing effects in the mouse which are most likely related to its psychostimulant-like pharmacological profile.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Bath salts; Conditioned place preference; Locomotor activity; MDPV; Oral self-administration; Reinforcement

Mesh:

Substances:

Year:  2017        PMID: 28866386      PMCID: PMC5708564          DOI: 10.1016/j.drugalcdep.2017.06.031

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  22 in total

1.  Contrasting effects of d-methamphetamine, 3,4-methylenedioxymethamphetamine, 3,4-methylenedioxypyrovalerone, and 4-methylmethcathinone on wheel activity in rats.

Authors:  Pai-Kai Huang; Shawn M Aarde; Deepshikha Angrish; Karen L Houseknecht; Tobin J Dickerson; Michael A Taffe
Journal:  Drug Alcohol Depend       Date:  2012-06-03       Impact factor: 4.492

2.  Death following recreational use of designer drug "bath salts" containing 3,4-Methylenedioxypyrovalerone (MDPV).

Authors:  Brittany L Murray; Christine M Murphy; Michael C Beuhler
Journal:  J Med Toxicol       Date:  2012-03

3.  Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States.

Authors:  Henry A Spiller; Mark L Ryan; Robert G Weston; Joanne Jansen
Journal:  Clin Toxicol (Phila)       Date:  2011-07       Impact factor: 4.467

4.  Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone.

Authors:  Heather A Borek; Christopher P Holstege
Journal:  Ann Emerg Med       Date:  2012-03-03       Impact factor: 5.721

Review 5.  The toxicology of bath salts: a review of synthetic cathinones.

Authors:  Jane M Prosser; Lewis S Nelson
Journal:  J Med Toxicol       Date:  2012-03

6.  Ethanol-induced CTA mediated by acetaldehyde through central catecholamine activity.

Authors:  C M Aragon; M Abitbol; Z Amit
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

7.  Pharmacological characterization of designer cathinones in vitro.

Authors:  L D Simmler; T A Buser; M Donzelli; Y Schramm; L-H Dieu; J Huwyler; S Chaboz; M C Hoener; M E Liechti
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

Review 8.  Synthetic cathinones: chemistry, pharmacology and toxicology of a new class of designer drugs of abuse marketed as "bath salts" or "plant food".

Authors:  M Coppola; R Mondola
Journal:  Toxicol Lett       Date:  2012-03-21       Impact factor: 4.372

9.  Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV).

Authors:  Lucas R Watterson; Peter R Kufahl; Natali E Nemirovsky; Kaveish Sewalia; Megan Grabenauer; Brian F Thomas; Julie A Marusich; Scott Wegner; M Foster Olive
Journal:  Addict Biol       Date:  2012-07-11       Impact factor: 4.280

10.  Illicit bath salts: not for bathing.

Authors:  Patrick B Kyle; Richard B Iverson; Raghavendran G Gajagowni; Lee Spencer
Journal:  J Miss State Med Assoc       Date:  2011-12
View more
  4 in total

Review 1.  How preclinical studies have influenced novel psychoactive substance legislation in the UK and Europe.

Authors:  Raquel Santos-Toscano; Amira Guirguis; Colin Davidson
Journal:  Br J Clin Pharmacol       Date:  2020-02-23       Impact factor: 4.335

2.  3,4-Methylenedioxypyrovalerone: Neuropharmacological Impact of a Designer Stimulant of Abuse on Monoamine Transporters.

Authors:  Charlotte P Magee; Christopher L German; Yasmeen H Siripathane; Peter S Curtis; David J Anderson; Diana G Wilkins; Glen R Hanson; Annette E Fleckenstein
Journal:  J Pharmacol Exp Ther       Date:  2020-05-08       Impact factor: 4.030

3.  Role of monoaminergic systems and ambient temperature in bath salts constituent 3,4-methylenedioxypyrovalerone (MDPV)-elicited hyperthermia and locomotor stimulation in mice.

Authors:  Brenda M Gannon; Adrian Williamson; Kenner C Rice; William E Fantegrossi
Journal:  Neuropharmacology       Date:  2017-09-05       Impact factor: 5.250

4.  Behavioural, Pharmacokinetic, Metabolic, and Hyperthermic Profile of 3,4-Methylenedioxypyrovalerone (MDPV) in the Wistar Rat.

Authors:  Rachel R Horsley; Eva Lhotkova; Katerina Hajkova; Barbara Feriancikova; Michal Himl; Martin Kuchar; Tomas Páleníček
Journal:  Front Psychiatry       Date:  2018-04-24       Impact factor: 4.157

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.